Infection Control Today
CONTINUE TO SITE >

OR WAIT 15 SECS

Infection Control Today
Spotlight
Bug of the MonthCOVIDMask RespiratorTSI Brand Insights
Topic
View MoreAdvanced TechnologyBug of the MonthDisinfection/Sterile ProcessingEnvironmental ServicesHAIsHand HygieneLong-Term CareOperating RoomPersonal Protective EquipmentVascular AccessView More
News
Media
Medical World NewsVideosWebinars
Conference
Publication
Infection Control TodaySupplements And Featured Publications
Resources
CME/CEPartnersSponsoredWhitepapers
Subscribe
eNewsletterPrint Subscription

  • Advertise
  • Editorial
  • Editorial Board
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Infection Control Today. All rights reserved.

Spotlight
  • Bug of the Month
  • COVID
  • Mask Respirator
  • TSI Brand Insights
TopicSee All >
  • Advanced Technology
  • Bug of the Month
  • Disinfection/Sterile Processing
  • Environmental Services
  • HAIs
  • Hand Hygiene
  • Long-Term Care
  • Operating Room
  • Personal Protective Equipment
  • Vascular Access
  • View More
  • Advertise
  • Editorial
  • Editorial Board
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Infection Control Today. All rights reserved.

Drug-Resistant Gonorrhea Could be the Next Superbug

March 30, 2010

The rise of multidrug resistance in gonorrhea-causing bacteria is threatening to make this sexually-transmitted infection extremely difficult to treat. Professor Catherine Ison, speaking at the Society for General Microbiology's spring meeting in Edinburgh, highlighted the very real possibility that strains of Neisseria gonorrheae resistant to all current treatment options could emerge in the near future.

Ison, from the Health Protection Agency (HPA) in London, described how some strains of the gonococcal bacteria that cause the disease are now showing decreased sensitivity to the current antibiotics used to treat them -- ceftriaxone and cefixime.

Gonorrhea is the second most common bacterial sexually-transmitted infection and if left untreated can lead to pelvic inflammatory disease, ectopic pregnancy and infertility in women. Current treatment consists of a single dose of antibiotic given in the clinic when prescribed, by mouth for cefixime and by injection for ceftriaxone.

"Choosing an effective antibiotic can be a challenge because the organism that causes gonorrhea is very versatile and develops resistance to antibiotics very quickly," explained Ison. "Penicillin was used for many years until it was no longer effective and a number of other agents have been used since. The current drugs of choice, ceftriaxone and cefixime, are still very effective but there are signs that resistance particularly to cefixime is emerging and soon these drugs may not be a good choice," she said.

Bacteria isolated from patients diagnosed with gonorrhea are tested for their susceptibility to various antibiotics to monitor patterns of resistance at a local and national level. Ongoing monitoring of antimicrobial resistance is critical to ensure that first-line treatments for gonorrhea remain effective. "There are few new drugs available and so it is probable that the current use of a single dose may soon need to be revised and treatment over several days or with more than one antibiotic will need to be considered," Ison warned. "If this problem isn't addressed then there is a real possibility that gonorrhea will become a very difficult infection to treat," she said.